Compare Stocks

→ Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BVXV BiondVax Pharmaceuticals		$1.36	$1.25 ▼ $11.80	$2.54M	2.37	127,289 shs	23,000 shs
CDTX Cidara Therapeutics	$0.73 -11.0%	$0.77	$0.59 ▼ $1.48	$66.15M	0.98	665,830 shs	1.26 million shs
ENTX Entera Bio	$2.29 -9.1%	$1.47	$0.52 ▼ $3.35	$65.95M	1.7	212,176 shs	552,922 shs
OTLK Outlook Therapeutics	$8.75 +1.5%	$8.60	$4.00 ▼ $40.60	$113.84M	0.04	556,900 shs	136,746 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BVXV BiondVax Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-24.02%
CDTX Cidara Therapeutics	+1.81%	-22.93%	+20.41%	+11.28%	-23.64%
ENTX Entera Bio	-15.44%	+29.23%	+83.94%	+129.09%	+194.91%
OTLK Outlook Therapeutics	-0.92%	-7.81%	+4.61%	+12.15%	-60.09%

Can't believe it's happening again (Ad)

One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.

We explain how this event works in full right here.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BVXV BiondVax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	3.804 of 5 stars	3.5	3.0	0.0	4.6	3.0	0.8	0.0
ENTX Entera Bio	1.6972 of 5 stars	3.5	3.0	0.0	0.0	3.8	0.0	0.0
OTLK Outlook Therapeutics	3.0482 of 5 stars	4.4	2.0	0.0	0.0	3.0	1.7	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BVXV BiondVax Pharmaceuticals	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	3.00	Buy	$4.67	539.27% Upside
ENTX Entera Bio	3.00	Buy	$10.00	336.68% Upside
OTLK Outlook Therapeutics	2.88	Moderate Buy	$46.43	430.57% Upside

Current Analyst Ratings

Latest CDTX, ENTX, BVXV, and OTLK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/8/2024	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
4/2/2024	ENTX Entera Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
3/27/2024	OTLK Outlook Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$50.00
3/25/2024	OTLK Outlook Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$30.00
2/16/2024	OTLK Outlook Therapeutics	Capital One Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
2/15/2024	OTLK Outlook Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$60.00
1/25/2024	OTLK Outlook Therapeutics	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$31.40
1/25/2024	OTLK Outlook Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$40.00

(Data available from 4/16/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BVXV BiondVax Pharmaceuticals	N/A	N/A	N/A	N/A	($3.81) per share	N/A
CDTX Cidara Therapeutics	$64.29M	1.03	N/A	N/A	($0.04) per share	-18.25
ENTX Entera Bio	$130K	507.32	N/A	N/A	$0.36 per share	6.36
OTLK Outlook Therapeutics	N/A	N/A	N/A	N/A	($1.11) per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BVXV BiondVax Pharmaceuticals	-$5.80M	-$2.55	N/A	N/A	N/A	N/A	-346.36%	-29.52%	N/A
CDTX Cidara Therapeutics	-$29.80M	-$0.39	N/A	N/A	N/A	-55.49%	-264.84%	-48.12%	5/9/2024 (Estimated)
ENTX Entera Bio	-$8.89M	-$0.31	N/A	N/A	N/A	N/A	-101.78%	-83.90%	5/3/2024 (Estimated)
OTLK Outlook Therapeutics	-$58.98M	-$4.00	N/A	N/A	N/A	N/A	-3,741.39%	-132.37%	5/20/2024 (Estimated)

Latest CDTX, ENTX, BVXV, and OTLK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/8/2024	Q4 2023	ENTX Entera Bio	-$0.08	-$0.07	+$0.01	-$0.07	N/A	N/A
2/14/2024	Q1 2024	OTLK Outlook Therapeutics	-$1.00	-$0.80	+$0.20	-$0.04	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BVXV BiondVax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
ENTX Entera Bio	N/A	N/A	N/A	N/A	N/A
OTLK Outlook Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BVXV BiondVax Pharmaceuticals	N/A	4.12	4.12
CDTX Cidara Therapeutics	N/A	1.62	1.55
ENTX Entera Bio	N/A	10.32	10.32
OTLK Outlook Therapeutics	N/A	0.44	0.44

Ownership

Institutional Ownership

Company	Institutional Ownership
BVXV BiondVax Pharmaceuticals	11.83%
CDTX Cidara Therapeutics	35.82%
ENTX Entera Bio	14.11%
OTLK Outlook Therapeutics	11.20%

Insider Ownership

Company	Insider Ownership
BVXV BiondVax Pharmaceuticals	6.03%
CDTX Cidara Therapeutics	7.43%
ENTX Entera Bio	8.90%
OTLK Outlook Therapeutics	5.30%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
BVXV BiondVax Pharmaceuticals	33	1.87 million	1.76 million	Not Optionable
CDTX Cidara Therapeutics	73	90.62 million	83.89 million	Optionable
ENTX Entera Bio	17	28.80 million	26.24 million	Optionable
OTLK Outlook Therapeutics	24	13.01 million	12.32 million	Not Optionable

CDTX, ENTX, BVXV, and OTLK Headlines

Source	Headline
	Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million globenewswire.com - April 15 at 4:15 PM
	Biotech on a Budget: 7 Stocks Under $10 With Huge Potential investorplace.com - April 15 at 12:54 PM
	Outlook Therapeutics (NASDAQ:OTLK) versus Vigil Neuroscience (NASDAQ:VIGL) Head-To-Head Contrast americanbankingnews.com - April 15 at 1:14 AM
	US Consumer Sentiment Falls Slightly as Outlook for Inflation Worsens msn.com - April 14 at 9:03 AM
	Microsoft Outlook 2010's Default Profile Pic Was Based on Bill Gates' 1977 Mug Shot? msn.com - April 14 at 9:03 AM
	Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Recommendation of "Moderate Buy" from Analysts americanbankingnews.com - April 13 at 4:32 AM
	Fed's Williams: Outlook is uncertain, Fed must be data-dependent fxstreet.com - April 11 at 6:05 PM
	National Gas’ Summer Outlook 2024: Stable supply, reduced exports energylivenews.com - April 11 at 6:05 PM
	ADB Outlook forecasts 7 % GDP growth in 2025 bbs.bt - April 11 at 6:05 PM
	Natural Gas Price Forecast: Moving Average Breakout Improves Bullish Outlook fxempire.com - April 11 at 1:44 AM
	Stock Market Today: Wall Street Falls After Hot Inflation Data Burns Hopes for a June Rate Cut msn.com - April 11 at 1:44 AM
	Bitdefender now has identity protection for Gmail and Outlook msn.com - April 11 at 1:44 AM
	Insiders are Piling into These 10 Healthcare Stocks in 2024 finance.yahoo.com - April 10 at 3:44 PM
	Users Complain Gmail Blocks Email From Microsoft Outlook—Here’s The Fix forbes.com - April 3 at 3:14 PM
	Outlook.com trips over Google's spam blocking rules msn.com - April 3 at 3:14 PM
	Yezan Munther Haddadin Purchases 1,882 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) Stock insidertrades.com - March 30 at 7:48 AM
	BTIG upgrades Outlook Therapeutics stock to buy, cites ONS-5010 success uk.investing.com - March 29 at 8:32 PM
	Outlook Therapeutics, Inc. (NASDAQ:OTLK) Director Yezan Munther Haddadin Acquires 1,882 Shares marketbeat.com - March 29 at 12:10 PM
	Outlook from the C-Suite: Freeman and GES Leaders Share Their Biggest Business Concerns tsnn.com - March 29 at 10:26 AM
	How to fight the new Windows Outlook app and keep Mail…for now pcworld.com - March 28 at 2:25 PM
	Outlook Therapeutics, Inc. (NASDAQ:OTLK) Short Interest Down 93.3% in March marketbeat.com - March 27 at 10:15 PM
	Buy Rating for Outlook Therapeutics: Promising FDA Developments and Strong Financial Position Support $50 Price Target markets.businessinsider.com - March 27 at 3:13 PM
	Outlook Therapeutics shares rise after 'buy' rating from BTIG msn.com - March 27 at 3:13 PM
	Outlook Therapeutics (NASDAQ:OTLK) Upgraded by BTIG Research to Buy marketbeat.com - March 27 at 8:30 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

BiondVax Pharmaceuticals

NASDAQ:BVXV

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Cidara Therapeutics

NASDAQ:CDTX

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Entera Bio

NASDAQ:ENTX

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and hGh for the GH deficiency. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Outlook Therapeutics

NASDAQ:OTLK

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial